Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 161,295

Document Document Title
WO/2019/008520A1
The present invention relates to a process for preparing the Alectinib or a pharmaceutically acceptable salt thereof using lesser reaction steps and also eliminating expensive and time- consuming column chromatography. The invention also...  
WO/2019/008029A1
The present invention relates to compounds of formula (I): wherein Q is O or S, R1 is a 6-membered heteroaryl group containing at least one nitrogen atom in the 6-membered ring structure, wherein R1 may optionally be substituted, and R2 ...  
WO/2019/009438A1
The present invention provides a novel immune checkpoint inhibitor which has not been reported before. Provided is an immune checkpoint inhibitor which is characterized by including, as an active ingredient, a plant fermentation produc...  
WO/2019/010447A1
The invention provides compositions and methods for administering a therapeutic agent to a patient, such as pharmaceutical compositions containing a blood product and a therapeutic agent selected from an anthracycline anti-cancer agent (...  
WO/2019/008128A1
The invention relates to the field of producing, identifying and selecting biological binding molecules, such as antibodies or fragments thereof, as well as diagnostic methods using same within the context of diagnosing cancer diseases, ...  
WO/2019/008507A1
The invention is directed to substituted azetidine derivatives. Specifically, the invention is directed to compounds according Formula I: (I) wherein C, D, L1,L2,L3,R1, R2, R4, R5, R6, z2, z4, z5, and z6are as defined herein; and salts t...  
WO/2019/008506A1
The invention is directed to substituted bridged cycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein X, a, b, C, D, L2, L3, Y1, Y2, R2, R4, R5, R6, z2, z4, z5, and z6 are as defi...  
WO/2019/008537A1
There is provided a medical compound comprising a synthetic flavone derivative, according to the formula (I) with allotment in position C-3 of a group as shown below: Formula (I) wherein at least two of R2-R6 a re H, and the remaining ar...  
WO/2019/007003A1
The present invention discloses a pyrazolo[3,4-d]pyrimidine derivative as shown by formula (I). The compound provided by the present invention has a significant effect on inhibiting growth of tumor cells, can be used for preventing and/o...  
WO/2019/010219A1
Immunostimulatory fusion molecules that include an immune cell targeting moiety and a cytokine molecule, pharmaceutical and formulations thereof, and methods of using and making the same, are disclosed.  
WO/2019/009693A1
The present invention relates to the use of the compound Cur-[G-2]-OH as a sensitiser in a wide range of multiresistant tumors, particularly glioblastoma, which are characterised by the overexpression of the Nrf2 pathway.  
WO/2019/008441A1
Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active age...  
WO/2019/007415A1
Disclosed are a furan-naphthoquinone-based sulfoximine derivative as shown in formula (I), a pharmaceutical composition containing the derivative and the use of the derivative as an STAT3 inhibitor.  
WO/2019/006803A1
Disclosed is the use of a recombinant CXCL16 and interferon-γ in the preparation of a drug for inhibiting the proliferation of diffuse large B-cell lymphoma cells. In particular, the recombinant CXCL16 is used in combination with the in...  
WO/2019/009412A1
The present invention addresses the problem of providing a novel compound having high LSD1 inhibitory activity, high selectivity for LSD1 inhibition, and/or having useful therapeutic effects for various diseases. One embodiment of the pr...  
WO/2019/010165A1
Increasing resistance to antibiotics necessitates discovery of new targets and strategies to combat bacteria. Ideal protein targets are required for viability across many species, are unique to prokaryotes to limit effects on the host an...  
WO/2019/008152A1
The present invention provides novel compounds of formula (I) that are useful as inhibitors of the PD-l/PD-Ll protein/protein interaction. The compounds may be used in the treatment of cancer, infectious diseases and neurodegenerative di...  
WO/2019/010298A1
Disclosed is a compound of formula (I) in which a, R1- R5 and X1 are as described herein. Also disclosed are a pharmaceutical composition containing the compound and a method of using the compound for treating cancer, such as renal cancer.  
WO/2019/007382A1
Disclosed are an indole-formamide derivative, a preparation method therefor and the use thereof in medicine. In particular, disclosed are an indole-formamide derivative as shown in general formula (I), a preparation method therefor, a ph...  
WO/2019/010255A1
Provided herein are methods and compositions related to Bifidobacterium animalis ssp. lactis useful as therapeutic agents.  
WO/2019/008239A1
The invention relates to the use of imeglimin for preventing and/or treating hepatocellular carcinoma.  
WO/2019/008487A1
The invention pertains to dispersible tablets comprising as active ingredient N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-th iazol-4-yl]-2- fluorophenyl}-2,6-difluorobenzenesulfonamide, methanesulfonate salt, processes for ...  
WO/2019/006881A1
The present invention relates to the technical field of biomedical materials, especially to a preparation method for a graft-modified xanthan gum nano-sized microgel: firstly preparing N,N-bis(acryloyl)cystamine, and then carrying out gr...  
WO/2019/008126A1
Crystalline form II of Compound A. HC1: (Formula) characterised by its X-ray powder diffraction diagram and solid-state 13C NMR spectrum, and pharmaceutical compositions containing it.  
WO/2019/009813A2
The disclosure provides a method of inhibiting proliferation of a cell, inhibiting m3C formation in a cell, inhibiting activity of Mettl8 in a cell, or activating ATM and p53 in a cell, the method comprising contacting the cell with a Me...  
WO/2019/008156A1
The present invention provides novel compounds of formula (I) that are useful as inhibitors of the PD-1/PD-L1 protein/protein interaction. The compounds may be used in the treatment of cancer, infectious diseases and neurodegenerative di...  
WO/2019/009355A1
The present invention provides: an assay method that uses a compound represented by formula (I) as a fluorescent probe molecule and that is for detecting the lipid peroxidation suppression activity of a test compound; an assay kit that u...  
WO/2019/006741A1
Disclosed is a preparation of Pulsatilla saponin B4 for injection, comprising Pulsatilla saponin B4 and a pharmaceutically acceptable excipient. The preparation is an aqueous injection or a lyophilized powder injection, more preferably a...  
WO/2019/008379A1
There is described bispecific antibodies which selectively bind to Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) and the CD3 subunit of the T-Cell Receptor (TCR), their production and their use. Also described is the use of the ...  
WO/2019/008064A1
The invention relates to vascular disrupting agent (VDA) such as combretastatins for treating avascular or hypovascular micro-tumors with a diameter below 20 mm.  
WO/2019/008129A1
The present invention relates to the field of the preparation, identification and selection of biological binding molecules such as antibodies or fragments thereof, and also the use thereof in the context of therapy and prophylaxis of ca...  
WO/2019/008378A1
There is described a chimeric antigen receptor (CAR) which comprises an antigen binding domain which selectively binds to Receptor Tyrosine Kinase Like Orphan Receptor (ROR1), and its use. Also described is a T cell comprising the CAR an...  
WO/2019/008365A1
The present invention relates to amethod of treating or preventing cancer in a subject, comprising targeting an expressed frameshift expressed frameshift indel neo-antigen.an expressed frameshift indel mutation.  
WO/2019/007974A1
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to ...  
WO/2019/009434A1
The present invention relates to: a compound that is formed by linking the α carbonyl group of aspartic acid directly or via a linker to at least 50% of all of the terminal groups of a dendritic polymer that has a plurality of terminal ...  
WO/2019/006548A1
A class of fluorinated 2,4-diaminopyrimidine compounds of Formula (I) have been prepared for use in the treatment of cancers and other MERTK related disorders. (Formula (I))  
WO/2019/010201A1
In one embodiment, the invention' provides a chimeric antigen receptor (CAR) T cell which is conjugated to a bi-functional molecule which is specific for both an extracellular binding domain of the chimeric antigen receptor (CAR) T cell ...  
WO/2019/007075A1
Provided is the use of an anti-S100A4 antibody, a substance causing a deficiency of S100A4 in the body and a substance capable of deleting S100A4-positive macrophages in the body in the preparation of a drug for treating an immune injury...  
WO/2019/007293A1
Disclosed are a compound as shown in formula I, and a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, wherein each symbol is as defined in the claims. The compound as shown in formula I has a good inhibitory a...  
WO/2019/007284A1
Disclosed are a new carbazolamide derivative as shown in general formula I and having the effect of regulating RORγt activity or a salt thereof and a preparation method therefor. Also disclosed is the use of the carbazolamide derivative...  
WO/2019/010231A1
The present disclosure provides prochelators as targeted prodrugs for cancer, such as prostate cancer, and methods of making and using the same.  
WO/2019/008025A1
The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylure...  
WO/2019/009437A1
The present invention seeks to improve the evaluating capability of an SAM evaluation system and confirm whether the same can be used in an evaluation system for spontaneous cancers, and uses this evaluation system to confirm whether the...  
WO/2019/006599A1
Provided are an HPV16 E7 40-74 antigen polypeptide, a coding gene of the antigen polypeptide, an expression vector for expressing the antigen polypeptide, and a host cell containing the expression vector. Also provided are uses of the co...  
WO/2019/008011A1
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer...  
WO/2019/007140A1
Disclosed is a 4-aminopyrimidine derivative used as an adenosine A2A receptor antagonist, having general structural formula (I). R1 is selected from halogen, cyano group, or trifluoromethyl; R2 is selected from pyrazolyl, pyrrolidyl, or ...  
WO/2019/007019A1
A psoralen polymernanoparticle preparation and a preparation method therefor, relating to the technical field of polymernanoparticle preparations. The psoralen polymernanoparticle preparation with a high encapsulation efficiency is prepa...  
WO/2019/008154A1
The present invention provides novel compounds of formula (I) that are useful as inhibitors of the PD-1/PD-L1 protein/protein interaction. The compounds may be used in the treatment of cancer, infectious diseases and neurodegenerative di...  
WO/2019/000682A1
The invention relates to a Rho-associated protein kinase (ROCK) inhibitor of formula (I), a pharmaceutical composition containing said Rho-associated protein kinase inhibitor, a preparation method thereof and an application of the ROCK f...  
WO/2019/002542A1
A combination comprising a MPS1 inhibitor of formula (I) or one of its addition salts with a pharmaceutically acceptable acid or base, and a taxane compound, and compositions and uses thereof.  

Matches 1 - 50 out of 161,295